Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism : A randomized controlled trial with losartan

Local cardiac renin-angiotensin systems may regulate left ventricular (LV) hypertrophic responses. The absence (deletion [D]) of a 287-bp marker in the ACE gene is associated with greater myocardial ACE levels and exercise-related LV growth than is its presence (insertion [I]), an effect potentially...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2001-01, Vol.103 (2), p.226-230
Main Authors: MYERSON, Saul G, MONTGOMERY, Hugh E, WHITTINGHAM, Martin, JUBB, Mick, WORLD, Michael J, HUMPHRIES, Steve E, PENNELL, Dudley J
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Cardiology. Vascular system
DNA Transposable Elements
Exercise
Gene Deletion
Genotype
Heart
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Homozygote
Humans
Hypertrophy, Left Ventricular - drug therapy
Hypertrophy, Left Ventricular - etiology
Losartan - therapeutic use
Male
Medical sciences
Peptidyl-Dipeptidase A - genetics
Polymorphism, Genetic
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Local cardiac renin-angiotensin systems may regulate left ventricular (LV) hypertrophic responses. The absence (deletion [D]) of a 287-bp marker in the ACE gene is associated with greater myocardial ACE levels and exercise-related LV growth than is its presence (insertion [I]), an effect potentially mediated through either increased activity of the cellular growth factor angiotensin II on the angiotensin type 1 (AT(1)) receptor or increased degradation of growth-inhibiting kinins. We sought to confirm ACE genotype-associated exertional LV growth and to clarify the role of the AT(1) receptor in this association. One hundred forty-one British Army recruits homozygous for the ACE gene (79 DD and 62 II) were randomized to receive losartan (25 mg/d, a subhypotensive dose inhibiting tissue AT(1) receptors) or placebo throughout a 10-week physical training program. LV mass, determined by cardiac magnetic resonance, increased with training (8.4 g, P:
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.103.2.226